The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.
Baqsimi is a nasal spray formulation of glucagon, already widely used as an injectable treatment for hypoglycaemia, which can occur when people with diabetes inadvertently take too much insulin.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback